Vitae's approach to value generation begins with a unique discovery engine. Vitae was founded with the goal to create a paradigm breakthrough in the field of structure-based drug design. CONTOUR™, the result of that effort, delivers superior drug design precision, novelty and speed for our discovery efforts against known, high value biologic targets. This powerful and advanced discovery tool, in the hands of Vitae's accomplished drug hunting team, has yielded high value drug candidates in multiple therapeutic areas, each with very large commercial potential.
Vitae's first and lead program is in renin inhibition, an industry target of 30+ years for the treatment of high blood pressure. Less than 24 months after program initiation, Vitae identified novel, patentable inhibitors that overcame the decades old traditional roadblocks of low bioavailability and high synthetic complexity. This rapid success is paving the way for a potential new treatment standard, and as a result of that success, Vitae and GlaxoSmithKline formed a significant partnership around the program in one of the largest preclinical deals of 2005.
Vitae's next program is in diabetes, a category of very high unmet medical need. This program is also advancing very rapidly, with multiple series of extremely potent, selective and patently distinct molecules discovered that are in later stage in vivo studies. As with renin, this program is attracting partner interest from multiple companies.
Based on these early successes, Vitae is currently expanding its discovery efforts in the fields of inflammation, cancer, CNS and metabolic disease.
Who We Are
Vitae is led by R&D and business teams that apply extensive pharmaceutical industry experience to drive an entrepreneurial, high impact company culture.
Vitae's accomplished R&D leaders have discovered and developed numerous blockbuster drugs, with annual sales ranging from hundreds of millions to billions of dollars. The team brings invaluable drug hunting insights and intuition into a drug discovery and development process centered around CONTOUR™, Vitae's breakthrough, proprietary structure-based drug discovery approach.
Vitae's seasoned business team has significant experience leading billion dollar pharmaceutical businesses, and successfully delivering value to company shareholders in multiple therapeutic categories. In addition, Vitae's business and R&D teams are supported by a sophisticated group of blue chip investors and renowned advisors.
Our Business Strategy
Vitae is singularly product-focused. We discover and advance promising compounds to create a robust and sustainable pipeline of high impact drugs.
Our strategies to achieve this goal are to:
- Seamlessly integrate two powerful discovery assets:
- Vitae's CONTOUR™ drug discovery platform. Vitae was founded with the goal to create a paradigm breakthrough in the field of structure-based drug design. CONTOUR™, the result, delivers superior drug design precision, novelty and speed, overcoming decades old drug discovery challenges and by rapidly creating and advancing potential solutions to today's highest value targets.
- World-class scientists delivering great science, who have the proven ability to discover, develop and deliver commercially successful drugs
- Focus on well validated targets that align with significant unmet medical needs and large potential market opportunities
- Seek strategically appropriate partnerships with global pharmaceutical companies when and where it will help leverage the value of Vitae's portfolio and will accelerate the progression of individual programs
- Continue to build a company centered on our core cultural values of innovation, results, urgency, teamwork and winning attitude, which we believe are essential for creating a great company and delivering significant value with important new medicines.
